Cerus Corp (NASDAQ: CERS) reported Q1 EPS of ($0.25), $0.10 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $9.7 million versus the consensus estimate of $10.36 million.

“We see 2015 as a market development year for the U.S., as we gain experience in how quickly blood centers are able to implement and introduce the product. Therefore, we are providing 2015 revenue guidance for our core European and Middle East markets of $36-38 million. In our guidance, we anticipate approximately 15-20% growth in kit demand from our core European and Middle Eastern markets, offset by a continued weak Euro to U.S. dollar exchange rate, negatively impacting revenue as reported in U.S. dollars."

For earnings history and earnings-related data on Cerus Corp (CERS) click here.